Delivery Order SPE2DB25D3018-SPE2DB25FUXQU
- Not listed
- The Defense Logistics Agency awarded a $7,353.02 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by July 22, 2025, with the place of performance located in Conshohocken, Pennsylvania. The delivery order represents a discrete transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025, with completion scheduled for August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $8,586.45 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract represents a firm fixed price, non-competitive delivery order with performance scheduled for completion by July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11,671.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 16, 2025, with completion scheduled for July 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUXQUDelivery Order
The Defense Logistics Agency awarded a $7,684.68 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml). This competitively awarded, firm fixed-price contract is classified as a child delivery order without set-aside designation and is scheduled for completion by June 3, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a primary pharmaceutical prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen serves military and veteran healthcare systems with a comprehensive portfolio of pharmaceutical products and medical supplies. The Dupixent delivery supports the federal government's medical procurement needs, with Dupixent being a specialty biologic medication used in the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 6/2/25 |